Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NASDAQ:IDYA

IDEAYA Biosciences Q3 2025 Earnings Report

IDEAYA Biosciences logo
$35.50 0.00 (0.00%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$35.49 -0.01 (-0.01%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

IDEAYA Biosciences EPS Results

Actual EPS
$1.33
Consensus EPS
-$0.12
Beat/Miss
Beat by +$1.45
One Year Ago EPS
N/A

IDEAYA Biosciences Revenue Results

Actual Revenue
$207.83 million
Expected Revenue
$59.98 million
Beat/Miss
Beat by +$147.85 million
YoY Revenue Growth
N/A

IDEAYA Biosciences Announcement Details

Quarter
Q3 2025
Date
11/4/2025
Time
Before Market Opens
Conference Call Date
Tuesday, November 4, 2025
Conference Call Time
6:00AM ET

Upcoming Earnings

IDEAYA Biosciences' Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 12, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

IDEAYA Biosciences' Q3 2025 Earnings ReleaseEarnings Release
(8-K)
IDEAYA Biosciences' Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

IDEAYA Biosciences Earnings Headlines

Ideaya Biosciences Inc (IDYA)
July 31 at 5:22 PM  |  fr.investing.comhttps://fr.investing.com/equities/ideaya-biosciences-inc-historical-data
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 31 at 6:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302839570.html
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
 |  Base Camp Trading (Ad)
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted ...
July 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ideaya-biosciences-announces-ide892-potential-100000590.html
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
July 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ideaya-biosciences-announces-ide892-a-potential-best-in-class-mta-cooperative-prmt5-inhibitor-initiates-part-2-monotherapy-expansion-in-the-phase-12-study-in-mtap-deleted-pancreatic-and-lung-cancers-302834359.html
IDEAYA Biosciences Inc IDYA
July 26, 2026  |  morningstar.comM
See More IDEAYA Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IDEAYA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IDEAYA Biosciences and other key companies, straight to your email.

About IDEAYA Biosciences

IDEAYA Biosciences (NASDAQ:IDYA) is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies. This platform supports the rapid progression of drug candidates from target validation through early clinical development. IDEAYA has entered strategic collaborations with established pharmaceutical partners to expand the reach of its synthetic lethality portfolio, leveraging complementary expertise in drug discovery, development, and commercialization.

Founded in 2016 and headquartered in South San Francisco, California, IDEAYA maintains research operations in the United States and collaborates with leading academic institutions and industry organizations worldwide. The company’s management team comprises experienced biopharmaceutical executives and oncology researchers who guide its mission to deliver precision medicines to patients with high-need cancers. IDEAYA continues to build on its scientific foundation to bring forward innovative treatments that address genetically defined subsets of tumors.

View IDEAYA Biosciences Profile
Earnings Tools